Skip to main content
Ajanta Pharma Ltd. logo

Ajanta Pharma Ltd. — Investor Relations & Filings

Ticker · AJANTPHARM ISIN · INE031B01049 LEI · 3358008XLYJJZBFBCK12 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country IN India
Listing BSE.NS AJANTPHARM

About Ajanta Pharma Ltd.

https://www.ajantapharma.com

Ajanta Pharma Ltd. is a specialty pharmaceutical organization engaged in the development, manufacturing, and marketing of high-quality finished dosage formulations. The company maintains a significant presence in specialized therapeutic segments, including ophthalmology, dermatology, cardiology, and pain management. It operates advanced research and development centers dedicated to creating complex generics and first-to-market products. With a global footprint, the firm serves diverse healthcare needs across the United States and various emerging markets in Asia and Africa. Its manufacturing infrastructure comprises multiple state-of-the-art facilities designed to meet international regulatory standards, ensuring the delivery of effective and affordable healthcare solutions. The company's strategic focus remains on niche product categories and branded generics, supported by a robust supply chain and a commitment to innovation in drug delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication from Ajanta Pharma Limited addressed to stock exchanges, providing a revised schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events and information. The content is about scheduling and correcting dates for investor meetings and explicitly states that discussions will be based on already published information. There is no financial data, no report attached or referenced as being published, and no detailed financial or management analysis. This is an announcement related to investor relations and scheduling, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-19 English
Pls find enclosed revised Intimation w.r.t Participation in Investor Conference
Regulatory Filings Classification · 75% confidence The document is an exchange intimation under SEBI LODR regarding the revised schedule of analyst/institutional investor meetings. It does not contain substantive financial data or the report itself, nor is it a specific report type (e.g., earnings release or investor presentation). It is a regulatory announcement to stock exchanges, fitting the fallback category “Regulatory Filings (RNS).”
2026-05-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter from Ajanta Pharma Limited addressed to stock exchanges, providing a schedule of upcoming analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events and information. The content is an announcement of scheduled meetings and explicitly states that discussions will be based on already published information. There is no financial data, report, or detailed presentation included. The document length is short (1752 characters), and it serves as an informational notice rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-19 English
Please find enclosed Intimation w.r.t Participation in Investor Conference.
Regulatory Filings Classification · 92% confidence The document is a notice under SEBI Listing Regulations providing the schedule of upcoming analyst and institutional investor meetings. It does not contain financial results, presentation materials, or an actual report; rather, it is a compliance/regulatory announcement. Therefore, it falls under Regulatory Filings (RNS).
2026-05-19 English
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 13, 2026 for Aayush Agrawal, trustee ....
Regulatory Filings Classification · 88% confidence The document is a mandatory disclosure by a promoter to stock exchanges regarding the creation and release of a pledge (encumbrance) on shares under SEBI (SAST) Regulations. It is a compliance/regulatory announcement to the exchanges, not a financial report, earnings release, or shareholder voting/results notice. It does not fit any specific category like Major Shareholding Notification (which covers share transfers/acquisitions) or Director’s Dealing (actual buy/sell trades). Therefore it falls under general regulatory filings.
2026-05-13 English
Pls find enclosed submission of Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Reg 24A of LODR.
Regulatory Filings Classification · 85% confidence The document is an Annual Secretarial Compliance Report for the year ended March 31, 2026, prepared by a Practicing Company Secretary under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It consists of detailed compliance tables and statutory references, and is being submitted to stock exchanges. This is a regulatory compliance filing rather than a financial report (10-K, IR) or earnings release. It best fits the “Regulatory Filings” category (RNS) as it is neither a pure announcement of a report (RPA) nor a standalone audit/annual report.
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.